RxDoctor Payments Data

Jing Dong, MD

Ophthalmology · Athens, GANPI 1356341119

Payments from drug & device makers

$6,566in general payments, 2019–2025

Across 277 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$536
  • Novartis$447
  • Glaukos Corporation$444
  • NEW World Medical,inc.$421
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$1532%
  • Food & beverage$6,34997%
  • Gifts$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,566 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$669,261
Medicare patients
1,773
Services billed
5,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine221$224,589
XiidraLifitegrast63$75,555
LumiganBimatoprost127$65,028
Cyclosporine79$60,162
CombiganBrimonidine Tartrate/Timolol72$28,963
Travoprost139$24,057
Prednisolone Acetate645$20,508
Brimonidine Tartrate487$15,968
Latanoprost1,435$15,938
Alphagan PBrimonidine Tartrate31$15,910
RocklatanNetarsudil Mesylat/Latanoprost21$11,501
Ketorolac Tromethamine611$10,470
VyzultaLatanoprostene Bunod24$8,817
RhopressaNetarsudil Mesylate18$6,064
Ciprofloxacin Hcl538$5,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,460$334,490451 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$128$84,37287 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$141$17,56539 claims
AlconSimbrinza$1,735$4,18621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →